Study: Natural supplement may reduce common-cold duration by only half a day

December 20, 2010

MADISON -- An over-the-counter herbal treatment believed to have medicinal benefits has minimal impact in relieving the common cold, according to research by the University of Wisconsin-Madison School of Medicine and Public Health.

The study, published in this month's Annals of Internal Medicine, involved echinacea, a wild flower (also known as the purple coneflower) found in meadows and prairies of the Midwestern plains. The supplement is sold in capsule form in drug and retail stores. Dried echinacea root has been used in homemade remedies such as teas, dried herb and liquid extracts.

The randomized trial involved more than 700 people between 12 and 80 years old. The subjects, all of whom had very early symptoms of a cold, were divided into four groups. One group received no pills, a second group received what they knew was echinacea, and a third group was given either echinacea or a placebo, but they did not know which. Participants recorded their symptoms twice a day for the duration of the cold, up to two weeks.

According to Bruce Barrett, the lead researcher and an associate professor of family medicine, patients receiving echinacea saw the duration of their cold reduced by seven to 10 hours. But he says this was not considered a significant decrease.

"Trends were in the direction of benefit, amounting to an average half-day reduction in the duration of a weeklong cold or an approximate 10 percent reduction in overall severity," he says. "However, this dose regimen did not make a large impact on the course of the common cold, compared either to blinded placebo or to no pills."

Barrett says a larger trial involving people who have found echinacea useful may help provide more answers. He adds that there were no side effects seen, so there is no reason that cold sufferers should stop using echinacea if they think it helps them.

"Adults who have found echinacea to be beneficial should not discontinue use based on the results of this trial, as there are no proven effective treatments and no side effects were seen," says Barrett.
-end-


University of Wisconsin-Madison

Related Placebo Articles from Brightsurf:

Effect of fluvoxamine vs placebo on clinical deterioration in outpatients with symptomatic COVID-19
This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects, versus placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction-confirmed mild COVID-19 illness.

Hydroxychloroquine no more effective than placebo in preventing COVID-19
Clinical trial with COVID-19 testing of participants shows health care workers in contact with coronavirus patients who took hydroxychloroquine each day did not reduce their rate of infection.

Compared to placebo, vitamin D has no benefit for severe asthma attacks
Contrary to earlier observational results, vitamin D supplements do not prevent severe asthma attacks in at-risk children, according to the first placebo-controlled clinical trial to test this relationship.

UMN trial shows hydroxychloroquine has no benefit over placebo in preventing COVID-19
Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.

The placebo effect and psychedelic drugs: tripping on nothing?
A new study from McGill suggests that, in the right context, some people may experience psychedelic-like effects from placebos alone.

Methotrexate reduces joint damage progression over placebo in erosive hand OA
According to new research findings presented at the 2019 ACR/ARP Annual Meeting, methotrexate did not demonstrate superior efficacy over placebo for pain relief and function evolution at three and 12 months in patients with erosive hand osteoarthritis, but did significantly reduce the progression of joint damage over placebo and seems to facilitate bone remodeling in these patients.

Botulinum toxin reduces chronic migraine attacks, compared to placebo
A growing body of evidence supports the effectiveness of botulinum toxin injections in reducing the frequency of chronic migraine headaches, concludes an updated review and analysis in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Opioids vs. placebo, nonopioid alternatives for chronic noncancer pain
An estimated 50 million adults in the United States were living with chronic noncancer pain in 2016 and many of them were prescribed opioid medications, even though a clinical benefit is uncertain.

Probiotic no better than placebo for acute gastroenteritis in children
While probiotics are often used to treat acute gastroenteritis (also known as infectious diarrhea) in children, the latest evidence shows no significant differences in outcomes, compared to a placebo.

Most common shoulder operation is no more beneficial than placebo surgery
In a landmark study published this week in the BMJ, Finnish researchers show that one of the most common surgical procedures in the Western world is probably unnecessary.

Read More: Placebo News and Placebo Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.